Overview

HDDO-1801 Intervention Trial

Status:
Unknown status
Trial end date:
2020-02-28
Target enrollment:
Participant gender:
Summary
A randomized, open-label, single-dose, 3-period, 6-sequence, 3-way crossover study
Phase:
Phase 1
Details
Lead Sponsor:
Hyundai Pharmaceutical Co., LTD.
Treatments:
Bepotastine besilate
Montelukast